Alimera Sciences to Present at the Cantor Fitzgerald Conference
Get Alerts ALIM Hot Sheet
Join SI Premium – FREE
ATLANTA, July 06, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ: ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the Cantor Fitzgerald Conference, to be held July 12 - 13, 2016 at Le Parker Meridien Hotel in New York, NY. The Company's presentation will take place Tuesday, July 12, 2016, at 2:30 PM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimeraciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences Alimera Sciences (NASDAQ: ALIM) (Alimera), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases . For more information, please visit www.alimerasciences.com.
Contact: CG CAPITAL 877.889.1972 [email protected]Source: Alimera Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Small Business, Big Trust: How Local Locksmiths Compete With National Call Centers
- Best Crypto to Buy Now Is Not ETH or SOL and Pepeto Proves Why Before
- TTW Announces the Top 50 Travel Solution Cards in the World for 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share